Abstract
Between February 1982 and April 1995, 62 patients (37 male, 25 female) with acute myelogenous leukemia (AML) with a median age of 32 years (19–51 years) received allogeneic marrow grafts from an HLA-identical sibling (n=60) or an HLA-mismatched family member (n=2). At the time of transplant, 35 patients were in first complete remission (CR), five in second CR, eight were primary refractory, eight were in untreated relapse and six in refractory relapse. The FAB subtypes were as follows: M1 (n=17), M2 (n=13), M3 (n=6), M4 (n=19), M5 (n=6), M6 (n=1). For conditioning most patients were given total body irradiation combined with cyclophosphamide (CY,n=50) or CY and busulfan (n=9). For graft-versus-host disease prophylaxis patients received cyclosporin A (CSA) and methotrexate (MTX) (n=32), MTX alone (n=12), CSA and methylprednisone (n=5), or CSA alone (n=13). As of April 1995, probability of leukemia-free survival projected at 10 years after BMT was 60% for patients transplanted in first CR compared with 10% for patients transplanted beyond first CR. Transplant-related mortality was 11% after BMT in first CR and 39% after BMT beyond first CR. Probability of relapse projected at 10 years after BMT is 32% for patients who received transplants in first CR and 81% for patients who received transplants beyond first CR. Thus, high-dose chemo/radiotherapy followed by allogeneic marrow infusion has a high curative potential for patients with AML who receive transplants in first CR and offers the chance of long-term disease-free survival for some patients with advanced disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Advisory Committee of the International Bone Marrow Transplant Registry (1989) Report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 4:221–228
Appelbaum FR Clift RA Buckner CD, Stewart P, Storb R, Sullivan KM, Thomas ED (1983) Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood 61:949–953
Buckner CD, Clift RA, Thomas ED, Sanders JE, Hackman R, Stewart PS, Storb R, Sullivan KM (1982) Allogeneic marrow transplantation for patients with acute non-lymphoblastic leukemia in second remission. Leuk Res 6:395–399
Clift RA, Buckner CD, Appelbaum F, Beatty P, Storb R, Deeg HJ, Doney K, Hansen J, Hill R, Martin P, Sanders J; Stewart P, Sullivan K, Witherspoon R, Thomas ED (1987) The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 2:243–258
Copelan EA, Biggs JC, Thompson JM, Crilley P, Szer J, Klein JP, Kapoor N, Avalos BR, Cunningham I, Atkinson K, Downs K, Harmon GS, Daly MB, Brodsky I, Bulova SI, Tutschka PJ (1991) Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 78:838–843
Gaiger A, Mannhafter C, Hinterberger W, Haas O, Marosi C, Kier P, Eichinger S, Funovic M, Lechner K (1991) Detection of engraftment and mixed chimerism following bone marrow transplantation using PCR amplification of a highly variable region-variable number of tandem repeats (VNTR) in the von Willebrand factor gene. Ann Hematol 63:227–228
Gale RP (1989) IBMTR analysis of bone marrow transplants in acute leukemia. Bone Marrow Transplant 4:83–87
ISCN (1985) An international system for human cytogenetic nomenclature. Hamden DG, Klinger HP (eds) Karger, Basel
Korninger L, Knoebl P, Laczika K, Mustafa S, Quehenberger P, Schwarzinger I, Lechner K, Jaeger U, Mannhalter C (1994) PML-RARa PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2–3 months. Br J Haematol 88:427–431
Mehta J, Powles R, Horton C, Milan S, Treleaven J, Tait D, Catovsky D (1994) Bone marrow transplantation for primary refractory acute leukaemia. Bone Marrow Transplant 14:415–418
Miller WH, Kakizuka A, Frankel SR, Warrell RP, DeBlasio A, Levine K, Evans RM, Dimitrovsky E (1992) Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Scie USA 89:2694–2698
Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Shadduck RK, Venkataramanan R (1991) Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant 7:461–465
Radich JP, Sanders JE, Buckner CD, Martin PJ, Petersen FB, Bensinger W, McDonald GB, Mori M, Schoch G, Hansen JA (1993) Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with totalbody irradiation-containing regimens. J Clin Oncol 11:304–313
Report from the Working Party on Leukaemia, European Group for Bone Marrow Transplantation (1988) Allogeneic bone marrow transplantation for leukaemia in Europe. Lancet 1:1379–1382
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729–735
Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, Schubert MM, Atkinson K, Thomas ED (1981) Chronic graft-versus-host disease in 52 pa tients: adverse natural course and successful treatment with combination immunosuppression. Blood 57:267–276
Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Loughran T, Martin P, Neiman P, Petersen FB, Sanders J, Singer J, Stewart P, Thomas ED (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720–1728
Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD (1975) Bone marrow transplantation. New Engl J Med 292:832–843, 895–902
Weaver CH, Clift RA, Deeg HJ, Storb R, Appelbaum FR, Bensinger W, Doney K, Hansen JA, Martin PJ, Sanders J, Sullivan KM, Thomas ED, Singer J, Witherspoon R, Buckner CD (1994) Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplant 14:885–893
Winston DJ, Gale RP (1991) Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Bone Marrow Transplant 8:7–11
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Greinix, H.T., Keil, F., Brugger, S.A. et al. Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia. Ann Hematol 72, 53–59 (1996). https://doi.org/10.1007/BF00641308
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00641308